One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
Clinical Ophthalmology · 2023-08 · Volume 17 · 2201-2208
DOI: 10.2147/opth.s424315 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Ophthalmology, 2023-08. Verfasst von Ryan B Rush. Beteiligte Einrichtung: Department of Ophthalmology, Panhandle Eye Group, Amarillo, TX, USA. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Panhandle Eye Group, Amarillo, TX, USA.
- Department of Ophthalmology, Southwest Retina Specialists, Amarillo, TX, USA.
- Department of Surgery, Texas Tech University Health Science Center, Amarillo, TX, USA.
ORCID-Profile: Ryan B Rush
Zitieren
APA
Rush, R. B. (2023). One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration. Clinical Ophthalmology, Volume 17, 2201-2208. https://doi.org/10.2147/opth.s424315
Vancouver
Rush RB. One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration. Clinical Ophthalmology. 2023;Volume 17:2201-2208. doi:10.2147/opth.s424315
BibTeX
@article{Rush2023,
author = {Rush, Ryan B},
title = {One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration},
journal = {Clinical Ophthalmology},
year = {2023},
volume = {Volume 17},
pages = {2201--2208},
doi = {10.2147/opth.s424315}
}
EUVIMED